恒瑞医药：注射用SHR-9839(sc)等多款药物临床试验获批

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for multiple clinical trial applications, indicating a significant advancement in its drug development pipeline [1] Group 1: Clinical Trials - The company and its subsidiaries, including Suzhou Shengdiya Biopharmaceutical Co., Ltd., Shanghai Heng Rui Medicine Co., Ltd., and Shanghai Shengdi Medicine Co., Ltd., have been granted clinical trial approval for several injectable drugs [1] - The approved drugs include SHR-9839(sc), SHR-A2009, SHR-1826, HRS-4642 injection, Adebali monoclonal antibody injection, and others [1] - A specific focus is on the Phase IB/II study of SHR-9839(sc) in combination with anti-tumor drugs, targeting safety, tolerability, and efficacy in solid tumor subjects [1]